Blog
FAQ Category: Patent Law
Procedural, legal, statutory, and regulatory elements of patent law. Sources may include 35 USC, 37 CFR, Manual of Patent Examining Procedure, and other sources.
-
How should unbranched nucleotide sequences be presented in patent applications?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What happens if a biological deposit referenced in a patent application becomes unavailable?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What happens to unamended patent claims in reexamination after a Board decision?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What types of persons typically file ex parte reexamination requests?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What are the typical circumstances where adequate written description issues arise in patent applications?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What types of treatments or prophylaxis are considered in Step 2A Prong Two?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What types of prior art can be submitted to the USPTO under 35 U.S.C. 301?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
Thirty minutes. Chief IP Officer on retainer — and the capital option behind it.
If what you need is something else, we’ll tell you on the same call.